United States Orthobiologics Market Outlook to 2033 - Orthobiologics, Cartilage Repair and Others
Summary
GlobalData’s “United States Orthobiologics Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Orthobiologics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Orthobiologics, Cartilage Repair and Others
The United States Orthobiologics Market report provides key information and data on -
Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2023 company share and distribution share data for Orthobiologics Market.
Global corporate-level profiles of key companies operating within the United States Orthobiologics Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
United States Orthobiologics is segmented as follows -
Bone Grafts and Substitutes
Bone Growth Stimulators
Cartilage Repair
Soft Tissue Biologics
Viscosupplementation
Reasons to Buy
The United States Orthobiologics Market report helps you to develop -
Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Orthobiologics Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Orthobiologics Market, United States
3.1 Orthobiologics Market, United States, Revenue ($m), 2018-2033
3.1.1 Bone Grafts and Substitutes Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.2 Bone Growth Stimulators Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.3 Cartilage Repair Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.4 Soft Tissue Biologics Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.5 Viscosupplementation Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Orthobiologics Market, United States, Volume (Units), 2018-2033
3.2.1 Bone Grafts and Substitutes Market, United States, Volume (Units), by Segment, 2018-2033
3.2.2 Bone Growth Stimulators Market, United States, Volume (Units), by Segment, 2018-2033
3.2.3 Cartilage Repair Market, United States, Volume (Units), by Segment, 2018-2033
3.2.4 Soft Tissue Biologics Market, United States, Volume (Units), by Segment, 2018-2033
3.2.5 Viscosupplementation Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Orthobiologics Market, United States, Average Price ($), 2018-2033
3.4 Orthobiologics Market, United States, Distribution Share by Revenue ($m), 2023
3.5 Orthobiologics Market, United States, Company Share by Revenue ($m), 2023
4 Overview of Key Companies in United States, Orthobiologics Market
4.1 Medtronic Plc
4.1.1 Company Overview
4.2 Sanofi
4.2.1 Company Overview
4.3 Bioventus Inc
4.3.1 Company Overview
4.4 Stryker Corp
4.4.1 Company Overview
4.5 Globus Medical Inc
4.5.1 Company Overview
4.6 Orthofix Holdings Inc
4.6.1 Company Overview
4.7 Zimmer Biomet Holdings Inc
4.7.1 Company Overview
4.8 Surgalign Holdings Inc
4.8.1 Company Overview
4.9 ZimVie Inc
4.9.1 Company Overview
4.10 AlloSource
4.10.1 Company Overview
4.11 LifeNet Health Inc
4.11.1 Company Overviewss
5 Orthobiologics Market Pipeline Products
6 Financial Deals Landscape
6.1 Debt Offerings
6.1.1 Zimmer Biomet Holdings to Raise Funds in Public Offering of Notes
6.1.2 Marrow Access Technologies Raises USD0.24 Million in Debt Offering
6.2 Equity Offerings
6.2.1 Lifecore Biomedical Raises USD24.3 Million in Private Placement of Common Stock
6.2.2 Ocugen Raises USD35 Million in Public Offering of Securities
6.2.3 Kolon TissueGene to Raise USD684.65 Million in Private Placement of Shares
6.2.4 Carmell Raises USD3 Million in Private Placement of Shares
6.2.5 Lineage Cell Therapeutics to Raise Up to USD40 Million in Public Offering of Common Stock
7 Recent Developments
7.1 Corporate Communications
7.1.1 Aug 21, 2024: AGFA HealthCare Announces the UK AGFA HealthCare User Group
7.1.2 Jul 05, 2024: Afamelanotide Assists DNA Repair Response Following UV Radiation
7.1.3 Mar 25, 2024: Stony Brook Professor George Leibowitz Assumes Role from Interim Dean Richard L. Edwards
7.1.4 Feb 05, 2024: Ultima Genomics to Launch UG 100 System and Present Data at AGBT
7.2 Financial Announcements
7.2.1 Aug 07, 2024: Zimmer Biomet Announces Second Quarter 2024 Financial Results
7.2.2 Aug 01, 2024: Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
7.2.3 Jul 31, 2024: ATEC Reports Second Quarter 2024 Financial Results And Raises Full-Year Guidance
7.2.4 Jul 29, 2024: Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
7.2.5 Jul 17, 2024: Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors
7.2.6 Jul 15, 2024: Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
7.2.7 Jul 10, 2024: ATEC to Report Second Quarter Financial Results on July 31, 2024
7.2.8 Feb 27, 2024: Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
7.2.9 Jan 04, 2024: Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
7.2.10 Oct 16, 2023: MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30
7.2.11 Oct 10, 2023: Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
7.3 Government and Public Interest
7.3.1 Jul 22, 2024: Arcutis to Host Zoryve (Roflumilast) Cream 0.15% FDA Approval Call with KOL
7.3.2 Jun 01, 2024: Typhoid Fever Vaccine “Tyfim V-I Injection Syringe” Information Regarding Obtaining Manufacturing and Sales Approval
7.3.3 May 07, 2024: Baxter to Present at Bank of America 2024 Health Care Conference
7.3.4 Oct 10, 2023: Twenty Years of the Nuvasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum
7.4 Legal And Regulatory
7.4.1 May 14, 2024: Valcare Medical Announces Enrollment of First Two Patients in AMEND TS EU Pilot Study
7.4.2 Mar 24, 2024: Ultradent Products Receives 510(K) Clearance For FORMA Composite (Shade A3D)
7.4.3 Mar 13, 2024: Edwards presents positive data from two valve studies at CRT 2024
7.5 Other Significant Developments
7.5.1 Feb 12, 2024: Tyber Medical Acquires FDA Clearance for Proximal Tibia Plating System
7.5.2 Oct 11, 2023: SINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants
7.6 Product News
7.6.1 Oct 31, 2023: Affamed Therapeutics Announced Positive Top-Line Results of Dextenza Inafter Cataract Surgery